Latest Articles
- Should I consider low-dose rivaroxaban (2.5 mg) for my patient with peripheral artery disease?
For patients with high ischemic risk, rivaroxaban 2.5 mg twice daily with aspirin 81 or 100 mg daily is a proven strategy to reduce major cardiovascular and limb events.
- How should I incorporate emergency contraception counseling into my practice?
Emergency contraception counseling should be provided routinely to women at risk of unintended pregnancy as part of counseling on reproductive goals.
- What is the optimal time for bone density screening in patients with premature ovarian insufficiency?
Dual-energy x-ray absorptiometry should be performed at diagnosis, with the timing of repeat scans predicated on the patient’s clinical risk factors for fracture.
Lipoprotein(a) in clinical practice: What clinicians need to knowElevated lipoprotein(a) by itself is not an indication for statin therapy, but its presence supports earlier or more aggressive preventive therapy.
- Thyroid eye disease: What’s the latest?
A better understanding of the pathophysiology of this autoimmune disorder has led to innovative insights into its treatment, but long-term management remains a challenge.
- Should we continue guideline-directed medical therapy in patients with heart failure with improved ejection fraction?
Therapy should be continued even if left ventricular ejection fraction improves, as normalization or improvement does not guarantee a permanent recovery.
- Multiple scabietic nodules on the scrotum in a patient living with HIV infection
A 21-year-old man presented with pruritic erythematous papules and nodules on the scrotum and linear keratotic burrows on the right wrist.
- Lipoprotein ‘little a’: More than a little target in the management of cardiovascular risk?
Lipoprotein(a) was once believed to play no contributory role in the development of cardiovascular disease. That storyline has since flipped.
